Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0014547 (focal epilepsy)
 1,627 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Tiagabine blocks the uptake by neurons or glia of synaptically released GABA resulting in prolonged GABAergic activity and decreased likelihood of epileptic seizures. We evaluated the cognitive and quality of life effects of tiagabine in a double-blind, add-on, placebo-controlled, parallel, multicenter, dose-response efficacy study in patients with focal epilepsy whose complex partial seizures were difficult to control. One hundred sixty-two patients provided cognitive and quality of life data for the analyses and received the following treatments: placebo (n = 57), 16 mg/d tiagabine (n = 34), 32 mg/d tiagabine (n = 45), or 56 mg/d tiagabine (n = 26) at a fixed-dose for 12 weeks after a 4-week dose titration period. Eight cognitive tests and three measures of mood and adjustment were administered during the baseline period and again during the double-blind period near the end of treatment (or at the time of dropout). The patient groups were similar at entry into the study. Results showed no clinically important changes with the addition of tiagabine on the test battery. Although this is an encouraging finding, it remains for future investigations to determine the cognitive and behavioral effects of tiagabine either as monotherapy or in relation to other antiepileptic drugs.
 ...
PMID:Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy. 910 94

Tiagabine (TGB) is a novel anti-epileptic drug providing new therapeutic possibilities to patients with focal seizures resistant to treatment. Since there is no clear algorithm for the best add-on therapy, the aim of our work was to establish factors that statistically significantly affect tiagabine efficacy and toxicity in patients with focal seizures. Data in the study were obtained from over 200 neurologists all over Poland. A group of 1307 patients aged from 3.5 to 80 years with drug-resistant focal epilepsy participated in the study. They were under observation for 16 weeks when receiving TGB as an add-on therapy. Prior to TGB treatment they had at least 1 seizure per month (mean 7.42 +/- 9.86) during the past 3 months. On the study completion 40.47% of the patients were seizure-free for at least a month. Two factors turned out to be significant for TGB efficacy: the number of drugs used since the onset of epilepsy (p = 0.005) and seizure type (p = 0.047). The best outcome was attained in patients with simple partial seizures. Co-medication with phenytoin was better than TGB + carbamazepine or TGB + valproic acid. The factor determining the presence of side effects was the rate of TGB dose increment during the first six weeks of treatment. Toxicity of TGB was not related to its target dose. Tiagabine is a safe and efficient anti-epileptic drug for children and adults with focal epilepsy. Efficacy of tiagabine treatment depends on the number of drugs administered since the epilepsy onset and on the type of seizures. A slow dose increment is crucial for safety of TGB treatment.
 ...
PMID:[Determinants of tiagabine (TGB) efficacy and safety. A Polish multicenter study of 1307 patients with focal epilepsy]. 1459 50